SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Events
Featured Reports
Apr 28, 2023
2022 Annual Report
May 06, 2022
2021 Annual Report

Press Releases

04 May
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout;
28 Apr
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
WATERTOWN, Mass. , April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today  announced that it plans to host a
21 Mar
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on active treatment
02 Mar
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - -   Continue to enroll patients in   ReiMMAgine , the   Phase 1/2 clinical trial of SEL-302 for the treatment of methylmalonic acidemia (MMA)  - - IND enabling studies
Stock Information
Stock Information
Information Request
Information Request
Financial Information
Financial Information
FAQ
FAQ